Axon (AXON) – Major News
-
Axon (AXON) Tops Q3 EPS by 26c; raises FY revenue outlook
-
Axon (AXON) Tops Q2 EPS by 49c; raises guidance
-
Axon (AXON) Tops Q1 EPS by 34c; Raises Outlook
-
Axon (AXON) Tops Q4 EPS by 19c, Offers Guidance
-
Axon (AXON) Tops Q3 EPS by 11c; Offers Guidance
-
Axon (AXON) Tops Q2 EPS by 5c, Offers Guidance
-
Axon (AXON) Tops Q1 EPS by 15c
-
Axon (AXON) Tops Q4 EPS by 28c
-
Axon (AXON) Surges Higher on Q3 Beat
-
Axon (AXON) Tops Q2 EPS by 16c
-
Axon (AXON) Tops Q1 EPS by 10c; Raises Outlook
-
Axovant Sciences (AXON) Tops Q4 EPS by 4c; Raises Outlook
-
Oxford BioMedica, Axovant Sciences (AXON) Enter $842.5M Agreement to Commercialize OXB-102
-
Axovant Sciences (AXON) CEO, COO and Several Directors Resign; Pavan Cheruvu Joins as CEO
-
Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy Endpoints
-
Axovant Sciences (AXON) Reports Q4 Loss of $0.53/Share
-
Axovant Sciences (AXON) Names David Hung as CEO
-
Axovant Sciences (AXON) Misses Q1 EPS by 2c; Enters Licensing Agreement with Qaam Pharma
-
Axovant Sciences Ltd. (AXON) Reports Q3 Loss Per Share of 64c
-
Axovant Sciences Ltd. (AXON) Tops Q2 EPS by 12c
-
Axovant Sciences Ltd. (AXON) Reports Q1 Loss of $0.35, Names CFO
-
Axovant Sciences Ltd. (AXON) Announces Statistically Significant Data from RVT-101 Phase 2 in AD
-
Axovant Sciences (AXON) IPO Opens Up 40%
-
Axovant Sciences (AXON) IPO Prices at Top End of Range
Back to AXON Stock Lookup